TP53 and neoplasm: In contrast, tumours with appreciable sizes were developed in mice injected with p53+/+ cells expressing shISG15 and p53−/− cells expressing 2KR mutant, even when doxorubicin was treated, indicating the involvement of p53 ISGylation in tumour suppression.